Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice

Laurie E. Steffen McLouth; Thomas W. Lycan; Beverly J. Levine; Jennifer Gabbard; Jimmy Ruiz; Michael Farris; Stefan C. Grant; Nicholas M. Pajewski; Kathryn E. Weaver; W. Jeffrey Petty

doi:10.1016/j.cllc.2019.11.015

Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice

Laurie E. Steffen McLouth, Thomas W. Lycan, Beverly J. Levine, Jennifer Gabbard, Jimmy Ruiz, Michael Farris, Stefan C. Grant, Nicholas M. Pajewski, Kathryn E. Weaver, W. Jeffrey Petty

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

The quality of life and symptom experience for metastatic lung cancer patients treated with immunotherapy or chemoimmunotherapy in routine care has not been described. In our survey of 60 metastatic lung cancer patients receiving these treatments, 20% to 40% reported moderate symptoms (eg, rash, muscle ache). Patient-reported outcomes need to be monitored in clinical practice, especially for patients with worse physical function.

Original language	English
Pages (from-to)	255-263.e4
Journal	Clinical Lung Cancer
Volume	21
Issue number	3
DOIs	https://doi.org/10.1016/j.cllc.2019.11.015
State	Published - May 2020

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc.

Funding

Supported in part by a Lung Cancer Initiative of North Carolina Research Fellow grant (to L.E.S.M.) and Wake Forest CTSA grant UL1TR001420. L.E.S.M. was supported by National Cancer Institute grant R25CA122061 (PI, Avis). This study was also supported by the Comprehensive Cancer Center of Wake Forest University (P30 CA012197). Supported in part by a Lung Cancer Initiative of North Carolina Research Fellow grant (to L.E.S.M.) and Wake Forest CTSA grant UL1TR001420 . L.E.S.M. was supported by National Cancer Institute grant R25CA122061 (PI, Avis). This study was also supported by the Comprehensive Cancer Center of Wake Forest University ( P30 CA012197 ).

Funders	Funder number
Comprehensive Cancer Center of Wake Forest University
Wake Forest CTSA	UL1TR001420
National Childhood Cancer Registry – National Cancer Institute	R25CA122061, P30CA012197
National Childhood Cancer Registry – National Cancer Institute
Comprehensive Cancer Center at Wake Forest Baptist Medical Center	P30 CA012197
Comprehensive Cancer Center at Wake Forest Baptist Medical Center

Keywords

Atezolizumab
Health-related quality of life
Nivolumab
Pembrolizumab
Performance status

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cllc.2019.11.015

Cite this

Steffen McLouth, L. E., Lycan, T. W., Levine, B. J., Gabbard, J., Ruiz, J., Farris, M., Grant, S. C., Pajewski, N. M., Weaver, K. E., & Petty, W. J. (2020). Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice. Clinical Lung Cancer, 21(3), 255-263.e4. https://doi.org/10.1016/j.cllc.2019.11.015

@article{8777adfb91fe4f57a181343719108a5a,

title = "Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice",

abstract = "The quality of life and symptom experience for metastatic lung cancer patients treated with immunotherapy or chemoimmunotherapy in routine care has not been described. In our survey of 60 metastatic lung cancer patients receiving these treatments, 20\% to 40\% reported moderate symptoms (eg, rash, muscle ache). Patient-reported outcomes need to be monitored in clinical practice, especially for patients with worse physical function.",

keywords = "Atezolizumab, Health-related quality of life, Nivolumab, Pembrolizumab, Performance status",

author = "\{Steffen McLouth\}, \{Laurie E.\} and Lycan, \{Thomas W.\} and Levine, \{Beverly J.\} and Jennifer Gabbard and Jimmy Ruiz and Michael Farris and Grant, \{Stefan C.\} and Pajewski, \{Nicholas M.\} and Weaver, \{Kathryn E.\} and Petty, \{W. Jeffrey\}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = may,

doi = "10.1016/j.cllc.2019.11.015",

language = "English",

volume = "21",

pages = "255--263.e4",

number = "3",

}

Steffen McLouth, LE, Lycan, TW, Levine, BJ, Gabbard, J, Ruiz, J, Farris, M, Grant, SC, Pajewski, NM, Weaver, KE & Petty, WJ 2020, 'Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice', Clinical Lung Cancer, vol. 21, no. 3, pp. 255-263.e4. https://doi.org/10.1016/j.cllc.2019.11.015

TY - JOUR

T1 - Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice

AU - Steffen McLouth, Laurie E.

AU - Lycan, Thomas W.

AU - Levine, Beverly J.

AU - Gabbard, Jennifer

AU - Ruiz, Jimmy

AU - Farris, Michael

AU - Grant, Stefan C.

AU - Pajewski, Nicholas M.

AU - Weaver, Kathryn E.

AU - Petty, W. Jeffrey

PY - 2020/5

Y1 - 2020/5

N2 - The quality of life and symptom experience for metastatic lung cancer patients treated with immunotherapy or chemoimmunotherapy in routine care has not been described. In our survey of 60 metastatic lung cancer patients receiving these treatments, 20% to 40% reported moderate symptoms (eg, rash, muscle ache). Patient-reported outcomes need to be monitored in clinical practice, especially for patients with worse physical function.

AB - The quality of life and symptom experience for metastatic lung cancer patients treated with immunotherapy or chemoimmunotherapy in routine care has not been described. In our survey of 60 metastatic lung cancer patients receiving these treatments, 20% to 40% reported moderate symptoms (eg, rash, muscle ache). Patient-reported outcomes need to be monitored in clinical practice, especially for patients with worse physical function.

KW - Atezolizumab

KW - Health-related quality of life

KW - Nivolumab

KW - Pembrolizumab

KW - Performance status

UR - http://www.scopus.com/inward/record.url?scp=85077364615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077364615&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2019.11.015

DO - 10.1016/j.cllc.2019.11.015

M3 - Article

C2 - 31917067

AN - SCOPUS:85077364615

SN - 1525-7304

VL - 21

SP - 255-263.e4

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 3

ER -

Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this